Our research group is committed to augmenting the scope of our study by broadening the sample cohort, thereby facilitating a more definitive assessment of the clinical efficacy of furmonertinib as an effective therapeutic treatment for individuals afflicted with NSCLC that exhibit EGFR exon20 ins and other gene mutant. This evidence concerns the gene EGFR and non-small cell lung carcinoma.